Sophiris Bio (SPHS) to Offer Common Shares and Warrants
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Sophiris Bio Inc. (NASDAQ: SPHS) ("Sophiris"), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced that it intends to offer and sell, subject to market and other conditions, its common shares and warrants to purchase additional common shares in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Piper Jaffray & Co. is acting as sole book-running manager for the offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Community Bank System (CBU) to Acquire Merchants Bancshares (MBVT) in ~$304M Deal
- American Midstream Partners (AMID), JP Energy Partners (JPEP) Enter ~$2B Merger Agreement
- Notable Mergers and Acquisitions 10/24: (T)/(TWX) (COL)/(BEAV) (GNW) (AMTD) (CBU)/(MBVT) (OASM)
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings, Hot Corp. News
Related EntitiesPiper Jaffray
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!